Download Now - The Burrill Report

More documents

Recommendations

Info

SEPTEMBER STATISTICSThe Burrill ReportBiggest Advancers and Decliners, September 2012TICKER COMPANY PRICE8/31/2012PRICE9/28/2012PRICECHANGEPERCENTCHANGEREASONADVANCERSSVNTSavientPharmaceuticals1.32 2.50 1.18 89.4 Won in court against Tang Capital’s accusations ofinsolvency.APPY AspenBio Pharma 1.50 2.77 1.27 84.7 Announced that it will begin a key clinical trial of itsproduct, AppyScore.SNSSSunesisPharmaceuticals3.17 5.63 2.46 77.6 Announced plans to add 225 patients to its on-going latestagetrial for Voxaroxin after receiving positive efficacydata in interim analysis.CBLI Cleveland BioLabs 1.65 2.68 1.03 62.4 Received FDA agreement on pivotal animal efficacystudies for the development of Entolimed as a radiationcountermeasure.IRIS IRIS International 12.70 19.52 6.82 53.7 Agreed to be acquired by Danaher Corporation for $19.50a share.ACHNAchillionPharmaceuticals7.03 10.41 3.38 48.0 Excitement over its non-interferon hepatitis C treatmentlead Bank of America and Deutsche Bank to raise rating to“buy”.AEZS Æterna Zentaris 2.86 4.20 1.34 47.0 “Buy” rating from Roth Capital propelled stock forward.SNTS Santarus 6.18 8.88 2.7 43.7 Announced positive top-line results from late-stage trial ofRifamycin SV MMX for the treatment of diarrhea.PRANACADDECLINERSPrana BiotechnologyLimitedACADIAPharmaceuticals1.66 2.37 0.71 42.8 Received recommendation to proceed with Alzheimer’sclinical trial from data safety monitoring board.1.78 2.53 0.75 42.1 Announced completion of patient enrollment in a late-stagetrial of its experimental Parkinson’s drug pimavanserin.PURE PURE Bioscience 2.81 1.05 -1.76 -62.6 Announced pricing of 3.7 million shares of common stock at$1.10 a share.PPHMQCORPeregrinePharmaceuticalsQuestcorPharmaceuticals2.54 1.03 -1.51 -59.4 Shares plunged after company reported that previouslyreleased mid-stage cancer drug data was unreliable due tothird-party error in conducting study.43.44 18.47 -24.97 -57.5 Announced that the U.S. government was investigating thecompany’s promotional practices.MAXY Maxygen 6.14 2.64 -3.50 -57.0 Company declared special dividend after reporting that Q2EPS fell 47 percent compared to the same quarter the yearbefore.ZLCS Zalicus 1.48 0.74 -0.74 -50.0 Reported that its experimental rheumatoid arthritis drug,Synavive, missed key secondary endpoint of meaningfulclinical benefit in a mid-stage study.GEVO Gevo 3.54 2.14 -1.4 -39.5 Announced plans to stop temporarily producing isobutanoland shift to ethanol production at its Minnesota facility.GERN Geron 2.76 1.71 -1.05 -38.0 Announded two setbacks for its experimental cancer drug,imetelstat, as it halted one mid-stage study and said that itdid not expect the drug to succeed in a second study.NDZ Nordion 10.43 6.75 -3.68 -35.3 Company was unsuccessful in its claims for performanceand monetary damages relating to AECL’s cancelledconstruction of its MAPLE facilities.PGNXProgenicsPharmaceuticals4.08 2.88 -1.20 -29.4 Eliminated a quarter of its staff and announced departureof CFO.nNovember 2012 24
SEPTEMBER STATISTICSThe Burrill ReportSeptember 2012 Venture FinancingsCOMPANYRAISED(USD M)PRINCIPAL FOCUSFINANCINGROUNDINVESTORSAragon Pharmaceuticals 50.0 Therapeutics Series D Topspin Fund; Aisling Capital; OrbiMed Advisors; The ColumnGroupFoundation Medicine 42.5 Diagnostics Series B Deerfield Managemenet; Casdin Capital; Redmile Group;Roche Venture Fund; WuXi Corporate Venture Fund; ThirdRock Ventures; Google Venture; Kleiner Perkins Caufield &ByersMyoKardia 38.0 Therapeutics Series A Third Rock VenturesTandem Diabetes Care 36.4 Medical devices Series D TPG Biotech; Delphi Ventures; Domain AssociatesIlluminOss Medical 28.0 Medical devices Series C Tekla Capital Management; Life Sciences Partners; FoundationMedical Partners; Mieza Capital; New Leaf Venture Partners;SR One; Excel Venture Management; Pappas Ventures; SlaterTechnology FundBioFire Diagnostics 25.0 Diagnostics Athyrium Opportunities FundSelexys Pharmaceuticals 23.0 Therapeutics Series A MPM Capital; other investorsBioMotiv 21.0 Therapeutics Series A, Part of$100M offeringAclaris Therapeutics 20.9 Therapeutics Series A Not disclosedTorax Medical 19.3 Medical devices Series D, part of$30M roundUniversity Hospitals; Harrington FamilyPiper Jaffray Merchant Banking; Sanderling Ventures; Thomas,McNerney & Partners; Accuitive Medical Ventures; KaiserPermanente; Mayo Medical VenturesiWalk 17.0 Medical devices Series D Gilde Healthcare Partners; WFD Ventures; General CatalystPartners; Sigma PartnersVital Therapies 16.0 Therapeutics First tranche of$76M roundExisting investorsArgos Therapeutics 16.0 Therapeutics 24 investorsIntercept Pharmaceuticals 15.0 Therapeutics Series C; secondclose of $50M roundOriGene Technologies 15.0 Tools/Technology Equity only Not disclosedOrbiMed Advisors; Genextra S.p.A [Italy]Agrivida 15.0 Industrial/Ag Series C Bright Capital Partners; Kleiner Perkins Caufield & Byers; DAGVentutres; Prairie Gold; Presidio; Gentry Venture Partners;Northgate Capital; Alexandria Real Estate Equities; SyngentaVenturesCatalyst Biosciences 13.4 Therapeutics Equity only Burrill & Company; other investorsClinipace 13.3 Tools/Technology Venture debt Six investorsCebix 13.0 Therapeutics Series B Sofinnova Ventures; InterWest Partners; Thomas McNereny &PartnersSteadyMed 12.8 Therapeutics Includes $2.4 raisedearlier in 2012BiO2 Medical 11.9 Medical devices Series C, part of$20M offeringInnovative PulmonarySolutions10.6 Medical devices Series B [closed inMarch]Forma Therapeutics 10.0 Therapeutics Existing investorsKB Partners; Samson Ventures; other investorsRemeditex Ventures; existing investorsAdvanced Technology Ventures; existing investorsWikiCell Designs 10.0 Industrial/Ag Series A Flagship Ventures; Polaris Venture PartnersApnex Medical 10.0 Medical devices New Enterprise AssociatesTactile Systems Technology 9.1 Medical devices Not disclosedAnnovation BioPharma 8.0 Therapeutics Series A Atlas Venture; Partners Innovation Fund; The MedicinesCompany(continued) ❱❱November 2012 25
Page 2 and 3: The Burrill ReportThe Burrill Repor
Page 5: The Burrill ReportThe Risk and Rewa
Page 10 and 11: The Burrill ReportTHIRD QUARTER STA
Page 12 and 13: THIRD QUARTER STATISTICSThe Burrill
Page 26 and 27: SEPTEMBER STATISTICSThe Burrill Rep
Page 28: SEPTEMBER STATISTICSThe Burrill Rep
Page 39 and 40: PIPELINEThe Burrill Report❱❱ (c
Page 45: PIPELINEThe Burrill Report❱❱ (c
Page 48 and 49: PIPELINEThe Burrill ReportUpcoming
Page 50 and 51: INDICESThe Burrill ReportBurrill Bi

Download Now - The Burrill Report

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?